Akston Biosciences Corporation is a leader in the field of insulin engineering. The company was founded in 2011 by the former SmartCells, Inc. team who developed the world’s first clinical glucose-responsive insulin (acquired by Merck & Co. in 2010). Combining its core expertise with modern biotechnology manufacturing techniques, Akston is developing new classes of biologic therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long acting insulin therapy, and oncology to dramatically improve both human and animal health. The company has raised over $18 million in equity financing from the management team and private investors, as well as $10 million from the NIH and the Helmsley Charitable Trust.